Evaluation of the usefulness of biomarkers for cardiac and skeletal myotoxicity in rats

Tonomura, Yutaka; Mori, Yoko; Torii, Mikinori; Uehara, Takeki

doi:10.1016/j.tox.2009.10.014

Cited by 60 publications

(49 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In contrast, plasma AST, FABP3, Myl3 and miR-133a were drastically elevated after TMPD treatment and the extent of the change was similar in both techniques. The large signalto-noise ratios seen with these biomarkers regardless of sampling technique indicate their diagnostic accuracy in line with the previous work (Pritt et al, 2008;Tonomura et al, 2009;Tonomura et al, 2012;Laterza et al, 2009). The kinetics of these biomarkers were somewhat different; plasma CK-MM and FABP3 were drastically elevated 7 hr after the TMPD treatment, whereas plasma AST, Myl3 and miR-133 reached maximum at 24 hr after the TMPD treatment.…”

Section: Discussionsupporting

confidence: 84%

“…Thus, it is critical that investigators should consider the kinetics of each biomarker response to various types of compounds depending on their mode of action when interpreting results of the studies. Overall, combinational measurement of these biomarkers could supply useful information for detecting potential toxicity and target tissues for new chemical entities in nonclinical toxicological studies as several authors pointed out (Pritt et al, 2008;Tonomura et al, 2009;Tonomura et al, 2012).…”

Section: Discussionmentioning

confidence: 99%

“…Recently, fatty acid binding protein 3 (FABP3) and myosin light chain 3 (Myl3) have been introduced into the toxicological field as promising biomarkers for skeletal myopathy (Pritt et al, 2008;Tonomura et al, 2009Tonomura et al, , 2012. Additionally, muscle specific microRNAs (e.g., miR-133a) have also been suggested as useful and reliable biomarkers for skeletal muscle injury in experimental animals (Laterza et al, 2009;Mizuno et al, 2011).…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Impact of different blood sampling techniques on plasma biomarkers for skeletal myopathy in conscious rats

Miwa

Tamai

Kinpara

et al. 2015

Fundam. Toxicol. Sci.

View full text Add to dashboard Cite

-To characterize variability of various musculoskeletal biomarkers by different blood sampling techniques in conscious rats, plasma asparate aminotransferase (AST), creatine kinase (CK) and its isoenzymes, fatty acid binding protein 3 (FABP3), myosin light chain 3 (Myl3) and microRNA (miR-133a) obtained by jugular venipuncture (C-JV) or tail venipuncture (C-TV) were compared with those obtained by jugular venipuncture (A-JV) in isoflurane-anesthetized rats. Plasma CK, FABP3 and Myl3, especially when collected by C-TV, were higher with larger variability than when collected by A-JV, whereas miR-133a displayed large variability in all techniques. Interestingly, higher CK obtained by C-JV or C-TV was largely attributable to higher CK-MM or CK-BB, respectively. Handling and restraint stress were identified as possible factors contributing to larger variability for CK, FABP3 and Myl3. A close correlation between CK and FABP3 was demonstrated both in the C-JV and C-TV techniques. Next, we evaluated the impact of C-JV and C-TV techniques for detecting skeletal myopathy in 2,3,5,6-tetramethyl-p-phenylenediamine-treated rats. In this model, CK and CK-MM obtained by C-TV were significantly increased, but those obtained by C-JV were not modified. In contrast, AST, FABP3, Myl3 and miR-133a obtained by both techniques were drastically elevated to a similar extent. The results suggest that, in conscious rats, the tail venipuncture technique may be more appropriate to detect skeletal myopathy despite the higher variability with this technique than with the jugular venipuncture technique. Furthermore, FABP3, Myl3 and miR-133a may serve as more sensitive biomarkers with large signal-to-noise ratios regardless of the blood sampling technique in conscious rats.

show abstract

Section: Discussionsupporting

confidence: 84%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Impact of different blood sampling techniques on plasma biomarkers for skeletal myopathy in conscious rats

Miwa

Tamai

Kinpara

et al. 2015

Fundam. Toxicol. Sci.

View full text Add to dashboard Cite

show abstract

“…ROC analysis was performed using a web-based calculator as previously reported (Eng, 2006;Tonomura et al, 2009). In brief, we defined urinalysis data of all four sampling points in the control group, and that of one sampling point on Day −1 in the treated group, as the non-renal injury data set, and that of three sampling points on Day 1 to 3 in the treated group as the renal injury data set.…”

Section: Roc Analysismentioning

confidence: 99%

Evaluation of the usefulness of urinary biomarkers for nephrotoxicity in rats

et al. 2010

Self Cite

View full text Add to dashboard Cite

“…Wide spectrum of skeletal muscle-and cardiac-specific miRNAs (miRNA-12, miRNA-133a, miRNA-124 and miRNA 208) miRNAs has been investigated as circulating biomarkers of myotoxicity [46]. Because several miRNAs have exhibit tissue specificity, stability in extracellular space, high conservation between preclinical test species, and might express as response on direct tissue injury, it has been suggested that signature of microRNAs might be useful as biomarkers of cardiac injury [47,48]. Calvano, et al [47] reported that miRNA-133a/b are sensitive and specific markers of skeletal muscle and cardiac toxicity and that miRNA-208 used in combination with miRNA-133a/b can be used to differentiate cardiac from skeletal muscle toxicity.…”

Section: Micrornasmentioning

confidence: 99%

Determination of early tumoricidal drug-induced cardiotoxicity with biological markers

Berezin¹

2016

J Transl Sci

View full text Add to dashboard Cite

Cardiotoxicity due to tumoricidal drug use is defined as an asymptomatic reduction in left ventricular (LV) ejection fraction (EF) of ≥ 10% to <55% or as a reduction of the LVEF of ≥ 5% to <55% with symptoms of heart failure (HF). The implementation in routine practices the highly tumoricidal anthracycline drugs, taxanes, and trastuzumab cause progressive LV dysfunction and symptomatic HF in dose-dependent manner. Despite there is potent reversibility of tumoricidal drug-induced cardiotoxicity, this adverse effect frequently consists continuously and might lead to limited response to medical treatment and worse survival sufficiently. The aim of the mini review is consideration the clinical evidence that supports the use of cardiac biomarkers for early detection of cardiotoxicity. The review is reported that the identification of cancer patient with increased risk of early cardiotoxicity would allow not only prevention and diagnosis of chemotherapy related cardiotoxicity but also administration of optimal dose and duration of chemotherapy. The predictive role of brain natriuretic peptides, cardiac troponins, microRNAs, S100A1 and inflammatory biomarkers (C-reactive protein) is discussed.

show abstract

Evaluation of the usefulness of biomarkers for cardiac and skeletal myotoxicity in rats

Cited by 60 publications

References 27 publications

Impact of different blood sampling techniques on plasma biomarkers for skeletal myopathy in conscious rats

Impact of different blood sampling techniques on plasma biomarkers for skeletal myopathy in conscious rats

Evaluation of the usefulness of urinary biomarkers for nephrotoxicity in rats

Determination of early tumoricidal drug-induced cardiotoxicity with biological markers

Contact Info

Product

Resources

About